Helga Rübsamen-Schaeff
Director/Board Member at 4SC AG
Helga Rübsamen-Schaeff active positions
Companies | Position | Start | End |
---|---|---|---|
MERCK KGAA | Director/Board Member | 09/05/2014 | - |
Independent Dir/Board Member | 09/05/2014 | - | |
4SC AG | Director/Board Member | 02/01/2015 | - |
Universitätsklinikum Bonn | Director/Board Member | - | - |
Merck Life Science KGaA | Director/Board Member | - | - |
Merck Healthcare KGaA | Chairman | - | - |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | Director/Board Member | 01/01/2006 | - |
Founder | 01/01/2006 | - | |
Deutsche Akademie der Naturforscher Leopoldina eV | Corporate Officer/Principal | - | - |
Johann Wolfgang Goethe-Universität Frankfurt am Main | Corporate Officer/Principal | 01/01/1988 | - |
E. Merck KG
E. Merck KG Pharmaceuticals: MajorHealth Technology E. Merck KG operates as a holding company with interest in pharmaceutical preparations. It acts as a general partner that holds the majority of shares of the public company Merck KGaA. Merck KG is the parent company of all Merck companies yet it does not have any operating businesses itself. It makes the entrepreneurial policy decisions for the Merck Group. The company is headquartered in Darmstadt, Germany. | Corporate Officer/Principal | - | - |
░░░░░░░░ ░░░░░░░░ ░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
Career history of Helga Rübsamen-Schaeff
Former positions of Helga Rübsamen-Schaeff
Companies | Position | Start | End |
---|---|---|---|
░░░░░░░ ░░░░ ░ ░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░ ░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Helga Rübsamen-Schaeff
University of Münster | Undergraduate Degree |
Statistics
International
Germany | 17 |
Operational
Corporate Officer/Principal | 8 |
Director/Board Member | 6 |
Founder | 2 |
Sectoral
Health Technology | 6 |
Commercial Services | 4 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
MERCK KGAA | Health Technology |
BAYER AG | Health Technology |
4SC AG | Health Technology |
Private companies | 11 |
---|---|
Bayer HealthCare AG
Bayer HealthCare AG Pharmaceuticals: MajorHealth Technology Bayer HealthCare AG provides healthcare, agriculture, plastics and chemical products. It is an independent company comprising five divisions: Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. The company covers the fields of animal health, genetically produced medicines, over the counter products, diagnostic products and prescription drugs. The company is headquartered in Leverkusen, Germany. | Health Technology |
AiCuris GmbH & Co. KG
AiCuris GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services AiCuris GmbH & Co. KG provides research and development services for antiviral and antibacterial agents. The firm develops drugs against viruses such as human cytomegalovirus, herpes simplex virus, hepatitis B virus and human immunodeficiency virus. The company was founded in March 2006 and is headquartered in Wuppertal, Germany. | Commercial Services |
Chemotherapeutic Research Institute Georg-Speyer-Haus | Miscellaneous |
Universitätsklinikum Bonn | |
Deutsche Akademie der Naturforscher Leopoldina eV | |
Deutsche Akademie der Technikwissenschaften eV
Deutsche Akademie der Technikwissenschaften eV Miscellaneous Commercial ServicesCommercial Services Deutsche Akademie der Technikwissenschaften eV advises on technical and technological issues for engineering and applied sciences. The private company is based in Munich, Germany. | Commercial Services |
Georg Speyer Haus | |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | Commercial Services |
Merck Healthcare KGaA | |
Merck Life Science KGaA | |
E. Merck KG
E. Merck KG Pharmaceuticals: MajorHealth Technology E. Merck KG operates as a holding company with interest in pharmaceutical preparations. It acts as a general partner that holds the majority of shares of the public company Merck KGaA. Merck KG is the parent company of all Merck companies yet it does not have any operating businesses itself. It makes the entrepreneurial policy decisions for the Merck Group. The company is headquartered in Darmstadt, Germany. | Health Technology |